An Open-label, Single-dose, Phase 1 Study to Evaluate the Pharmacokinetics of Selatogrel in Subjects With Mild and Moderate Hepatic Impairment Compared to Matched Healthy Subjects

Viatris Innovation GmbH1 个研究点分布在 1 个国家目标入组 24 人开始时间: 2020年7月22日最近更新: 2025年7月4日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Viatris Innovation GmbH
入组人数: 24
试验地点: 1
主要终点: Plasma protein binding of selatogrel

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of mild and moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of selatogrel (ACT-246475).

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Sequential
主要目的: Other
盲法: None

入排标准

年龄范围: 18 Years 至 79 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•All participants (Groups 1,2 and 3)
•Signed informed consent in a language understandable to the participant prior to any study-mandated procedure.
•Male or female participant aged between 18 and 79 years (inclusive) at screening.
•Body mass index of 18.0 to 35.0 kg/m2 (inclusive) at screening.
•Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 (pre-dose). They must consistently and correctly use (from screening, during the entire study, and for at least 30 days after last study treatment administration) an acceptable effective method of contraception method, be sexually inactive, or have a vasectomized partner. If a hormonal contraceptive is used, it must have been initiated at least 1 month before treatment administration.
•Women of non-childbearing potential.
•Additional principal inclusion criteria for participants with hepatic impairment (Groups 1 and 2)
•Hepatic impairment due to liver cirrhosis according to the Child-Pugh classification:
•Group 1: Mild hepatic impairment, Child-Pugh A = score 5-
•Group 2: Moderate hepatic impairment, Child-Pugh B = score 7-
•Systolic blood pressure (SBP) 95-160 mmHg, diastolic blood pressure (DBP) 60-95 mmHg, and pulse rate 50-100 bpm (inclusive), measured on the same arm, after 5 minutes in the supine position at screening and on Day 1 (pre-dose).
•Estimated glomerular filtration rate (eGFR) at screening using the Modification of Diet in Renal Disease (MDRD) formula of:
•greater than or equal to 60 mL/min/1.73 m2 for participants with mild hepatic impairment (Group 1)
•greater than or equal to 45 mL/min/1.73 m2 for participants with moderate hepatic impairment (Group 2).
•Stable concomitant medications for at least 3 weeks prior to screening and up to Day 1 and expected to be stable during the conduct of the study.
•Additional principal inclusion criteria for healthy participants (Group 3)
•Normal blood pressure measured on the same arm, after 5 minutes in the supine position at screening and on Day 1 pre-dose defined as:
•SBP 90 to 140 mmHg, DBP 60 to 90 mmHg, and pulse rate 50 to 100 bpm (inclusive) for participants less than 60 years of age.
•SBP 95 to 160 mmHg, DBP 65 to 95 mmHg, and pulse rate 50 to 100 bpm (inclusive) for participants 60 years and older.
•eGFR greater than or equal to 80 mL/min/1.73 m2 at screening using the MDRD formula.

排除标准

•All participants (Groups 1, 2 and 3)
•Pregnant or lactating woman.
•Previous exposure to selatogrel.
•Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
•Known hypersensitivity to P2Y12 receptor antagonists or any excipients of the drug formulation.
•Known platelet disorders.
•Legal incapacity or limited legal capacity at screening.
•Additional exclusion criteria for participants with hepatic impairment (Groups 1 and 2)
•History or clinical evidence of any disease and/or existence of any surgical or medical condition (e.g., cholecystectomy), which might interfere with the absorption, distribution, metabolism, and excretion (ADME) of the study treatment (except for hepatic impairment, appendectomy, and herniotomy).
•Acute hepatitis, hepatic cancer, primary biliary cirrhosis, or any form of cholestatic disease.
•Clinical evidence or suspected acute liver failure as judged by the investigator.
•Severe ascites and/or pleural effusion.
•Encephalopathy greater than grade
•Clinical evidence of current alcohol or drug abuse.
•Clinically relevant abnormalities on a 12-lead ECG, except for abnormalities related to hepatic impairment, after 5 minutes in the supine position at screening and on Day 1 pre-dose.
•Additional exclusion criteria for healthy participants (Group 3)
•History or clinical evidence of any disease and/or existence of any surgical or medical condition (e.g., cholecystectomy), which might interfere with the ADME of the study treatment (except for appendectomy and herniotomy).
•History or clinical evidence of alcohol or drug abuse within the 3 years prior to screening.
•Family or personal history of prolonged bleeding or bleeding disorders, intracranial vascular diseases, stroke, reasonable suspicion of vascular malformations, or peptic ulcers.
•Previous treatment with any prescribed medications or over-the-counter medications within 2 weeks or 5 times the terminal half-life (t½), whichever is longer prior to study treatment administration (excludes contraceptives and hormone replacement therapy).

研究组 & 干预措施

Participants with mild hepatic impairment (Group 1)

Experimental

Participant with Child-Pugh Grade A Score of 5-6.

干预措施: Selatogrel (Drug)

Participants with moderate hepatic impairment (Group 2)

Experimental

Participant with moderate hepatic impairment with a Child-Pugh Grade B Score of 7-9.

干预措施: Selatogrel (Drug)

Healthy participants (Group 3)

Experimental

干预措施: Selatogrel (Drug)

结局指标